-
PPF Group Sells Sake in NBE-Therapeutics to Boehringer Ingelheim
americanpharmaceuticalreview
December 31, 2020
PPF Group has announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) ...
-
Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction
contractpharma
December 11, 2020
PPF Group, an international investment group, has signed an agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim.
-
PPF and SOTIO Invest $6.5 Million in MaveriX Oncology and its Lead Program MVX-5005
b3cnewswire
October 15, 2019
SOTIO, together with PPF, and MaveriX Oncology, Inc., announce the investment of PPF Group in MaveriX Oncology Inc., a private biotech company with a proprietary pipeline of targeted ...
-
PPF Expands its Investment in the Healthcare Sector Through Acquisition of Significant Stake in T Cell Therapy Company Autolus Therapeutics
b3cnewswire
September 17, 2019
PPF announces the acquisition of a 19.2% stake in Autolus Therapeutics plc, a leader in next-generation T cell programming technologies. The shares were acquired in the market through NASDAQ.
-
SOTIO and PPF Complete Acquisition of Cytune Pharma
b3cnewswire
August 31, 2018
SOTIO, a biotechnology company owned by the PPF Group, announces today the completion of the acquisition of Cytune Pharma by PPF.